Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study

INTRODUCTION: Patients with relapsed or refractory multiple myeloma (RRMM) represent an unmet clinical need. Belantamab mafodotin (belamaf; GSK2857916) is a first-in-class antibody–drug conjugate (ADC; or immunoconjugate) that delivers a cytotoxic payload, monomethyl auristatin F (MMAF), to myeloma...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Ophthalmol Ther
Hoofdauteurs: Farooq, Asim V., Degli Esposti, Simona, Popat, Rakesh, Thulasi, Praneetha, Lonial, Sagar, Nooka, Ajay K., Jakubowiak, Andrzej, Sborov, Douglas, Zaugg, Brian E., Badros, Ashraf Z., Jeng, Bennie H., Callander, Natalie S., Opalinska, Joanna, Baron, January, Piontek, Trisha, Byrne, Julie, Gupta, Ira, Colby, Kathryn
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Springer Healthcare 2020
Onderwerpen:
Original Research
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7708586/
https://ncbi.nlm.nih.gov/pubmed/32712806
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40123-020-00280-8
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items